Hormonal contraception in women with the metabolic syndrome: A narrative review

References

• Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.
   PubMed Web of Science ®Google Scholar
• Simmons RK, Alberti KGMM, Gale EAM, et al The metabolic syndrome: Useful concept or clinical tool? Report of a WHO expert consultation. Diabetologia 2010;53:600–5.
   PubMed Web of Science ®Google Scholar
• Reaven GM. The metabolic syndrome: Requiescat in pace. Clin Chem 2005;51:931–8.
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038–49.
   PubMed Web of Science ®Google Scholar
• Shroff R, Syrop CH, Davis W, et al Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389–95.
   PubMed Web of Science ®Google Scholar
• Tomlinson J, Millward A, Stenhouse E, et al Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: What are the risks and can they be reduced? Diabetic Med 2010;27:498–515.
   PubMed Web of Science ®Google Scholar
• Lauenborg J, Mathiesen E, Hansen T, et al The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005;90:4004–10.
   PubMed Web of Science ®Google Scholar
• Yeung EH, Hu FB, Solomon CG, et al Life-course weight characteristics and the risk of gestational diabetes. Diabetologia 2010;53:668–78.
   PubMed Web of Science ®Google Scholar
• Ferrara A. Increasing prevalence of gestational diabetes mellitus: A public health perspective. Diabetes Care 2007;30(Suppl. 2):S141–6.
   PubMed Web of Science ®Google Scholar
• March WA, Moore VM, Willson KJ, et al The prevalence of polycystic ovary syndrome in a community sample under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51.
   PubMed Web of Science ®Google Scholar
• Clark MK, Dillon JS, Sowers M, et al Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes 2005;29:1252–8.
   PubMed Web of Science ®Google Scholar
• Montague CT, O'Rahilly S. The perils of portliness: Causes and consequences of visceral adiposity. Diabetes 2000;49:883–8.
   PubMed Web of Science ®Google Scholar
• Beksinska ME, Smit JA, Kleinschmidt I, et al Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception 2010;81:30–4.
   PubMed Web of Science ®Google Scholar
• Xiang AH, Kawakubo M, Buchanan TA, et al A longitudinal study of lipids and blood pressure in relation to method of contraception in Latino women with prior gestational diabetes mellitus. Diabetes Care 2007;30:1952–8.
   PubMed Web of Science ®Google Scholar
• Westhoff C, Jain JK, Milsom I, et al Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception 2007;75:261–7.
   PubMed Web of Science ®Google Scholar
• Brache V, Faundes A, Alvarez F, et al Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002;65:63–74.
   PubMed Web of Science ®Google Scholar
• Korver T, Dieben T, Vree M, et al A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day and levonorgestrel 30 μg/day. Eur J Contracept Reprod Health Care 1998;3:169–78.
   PubMedGoogle Scholar
• Gallo MF, Lopez LM, Grimes DA, et al Combination contraceptives: Effects on weight. Cochrane Database Syst Rev 2008;CD003987.
   Google Scholar
• Milsom I, Lete I, Bjertnaes A, et al Effects on cycle control and bodyweight of the combined contraceptive ring, Nuvaring, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304–11.
   PubMed Web of Science ®Google Scholar
• Piccoli A, Crosignani PG, Nappi C, et al Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women. Nutr J 2008;7:21.
   PubMedGoogle Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2000;85:3161–8.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471–8.
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Álvarez-Blasco F, Botella-Carretero JI, et al Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453–61.
   PubMed Web of Science ®Google Scholar
• Hoeger K, Davidson K, Kochman L, et al The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299–306.
   PubMed Web of Science ®Google Scholar
• Edelman AB, Carlson NE, Cherala G, et al Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009;80:119–27.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Fraser IS, Lacarra M, et al Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 1999;59:311–8.
   PubMed Web of Science ®Google Scholar
• Trussell J, Schwarz EB, Guthrie KA. Obesity and oral contraceptive failure. Contraception 2009;79:334–8.
   PubMed Web of Science ®Google Scholar
• Smallwood GH, Meador ML, Lenihan JP, et al Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799–805.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Trummer D, et al Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16–25.
   PubMed Web of Science ®Google Scholar
• Trussell J, Guthrie KA, Schwarz EB. Much ado about little: Obesity, combined hormonal contraceptive use and venous thrombosis. Contraception 2008;77:143–6.
   PubMed Web of Science ®Google Scholar
• Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 2003;26:216–25.
   PubMed Web of Science ®Google Scholar
• Hedderson MM, Ferrara A, Williams MA, et al Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus. Diabetes Care 2007;30:1062–8.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Jokela M, Akbaraly TN, et al Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009;373:2215–21.
   PubMed Web of Science ®Google Scholar
• Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: Glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 1971;114:378–92.
   Web of Science ®Google Scholar
• Bonds DE, Lasser N, Qi L, et al The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial. Diabetologia 2006;49:459–68.
   PubMed Web of Science ®Google Scholar
• Rochira V, Madeo B, Zirilli L, et al Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: Evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men. Diabetic Med 2007;24:1491–5.
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Lee S, Chen H, et al Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15–26.
   PubMed Web of Science ®Google Scholar
• Xiang AH, Kawakubo M, Kjos SL, et al Long-acting injectable progestin contraception and the risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 2006;29:613–7.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Hau Hien Le M, Musherraf Z, et al Intermediate-term glucose tolerance in women with a history of gestational diabetes: natural history and potential associations with breastfeeding and contraception. Am J Obstet Gynecol 2008;198:699.e1–8.
   PubMedGoogle Scholar
• Cagnacci A, Tirelli A, Cannoletta M, et al Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. Contraception 2005;72:443–6.
   PubMed Web of Science ®Google Scholar
• Vicente L, Mendonça D, Dingle M, et al Etonogestrel implant in women with diabetes mellitus. Eur J Contracept Reprod Health Care 2008;13:387–95.
   PubMed Web of Science ®Google Scholar
• Kivelä A, Ruuskanen M, Ågren U, et al The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001;6:71–7.
   PubMed Web of Science ®Google Scholar
• Rogovskaya S, Rivera R, Grimes DA, et al Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005;105:811–5.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: A randomized trial. Contraception 2009;79:111–6.
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch KE, Darensbourg C, Ogden B, et al Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007;76:348–56.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli, et al Route of administration of contraceptives containing desogestrel/etonogestrel and insulin sensitivity: A prospective randomized study. Contraception 2009;80:34–9.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2009;CD006133.
   Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, et al Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2003;88:148–56.
   PubMed Web of Science ®Google Scholar
• Cibula D, Fanta M, Vrbikova J, et al The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005;20:180–4.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Renzi A, et al Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003;88:3621–5.
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–23.
   PubMed Web of Science ®Google Scholar
• Villaseca P, Hormaza P, Cárdenas I, et al Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: Lipid and carbohydrate changes. Eur J Contracept Reprod Health Care 2004;9:155–65.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, et al Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116–23.
   PubMed Web of Science ®Google Scholar
• Lemay A, Dodin S, Turcot L, et al Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006;21:121–8.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Deligeoroglou E, et al Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006;85:420–7.
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Pawelczyk L, Spaczynski RZ, et al Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007;92:456–61.
   PubMed Web of Science ®Google Scholar
• Åkerlund M, Almström E, Högstedt S, et al Oral contraceptive tablets containing 20 and 30 μg of ethinyl estradiol with 150 μg desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 1994;73:136–43.
   PubMed Web of Science ®Google Scholar
• Skouby SO, Endrikat J, Düsterberg B, et al A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel. Contraception 2005;71:111–7.
   PubMed Web of Science ®Google Scholar
• Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409–16.
   PubMed Web of Science ®Google Scholar
• Creasy GW, Fisher AC, Hall N, et al Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol: Effects on the lipid profile. J Reprod Med 2003;48:179–86.
   PubMed Web of Science ®Google Scholar
• Tuppurainen M, Klimscheffskij R, Venhola M, et al The combined contraceptive vaginal ring (Nuvaring®) and lipid metabolism: a comparative study. Contraception 2004;69:389–94.
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen JS, Ruokonen A, et al Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:269–75.
   PubMed Web of Science ®Google Scholar
• Skouby SO, Kühl C, Mølsted-Pedersen L, et al Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol 1985;153:495–500.
   PubMed Web of Science ®Google Scholar
• Kjos SL, Shoupe D, Douyan S, et al Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: Results of a controlled, randomized, prospective study. Am J Obstet Gynecol 1990;163:1822–7.
   PubMed Web of Science ®Google Scholar
• Kayikcioglu F, Gunes M, Ozdegirmenci O, et al Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: A 1-year follow-up study. Contraception 2006;73:528–31.
   PubMed Web of Science ®Google Scholar
• Biswas A, Viegas OAC, Roy AC. Effect of Implanon® and Norplant® subdermal contraceptive implants on serum lipids – a randomized comparative study. Contraception 2003;68:189–93.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon® on cardiovascular risk factors. Clin Endocrinol 2008;68:355–60.
   PubMed Web of Science ®Google Scholar
• Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism. Contraception 2001;64:295–9.
   PubMed Web of Science ®Google Scholar
• Chasan-Taber L, Willett WC, Manson JE, et al Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483–9.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Mohllajee AP, Martins SL, et al Combined oral contraceptive use among women with hypertension: A systematic review. Contraception 2006;73:179–88.
   PubMed Web of Science ®Google Scholar
• Sica DA. Drospirenone: An antihypertensive in waiting. Hypertension 2006;48:205–6.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816–21.
   PubMed Web of Science ®Google Scholar
• Gaffield ME, Curtis KM, Mohllajee AP, et al Medical eligibility criteria for new contraceptive methods: Combined hormonal patch, combined hormonal ring and the etonogestrel implant. Contraception 2006;73:134–44.
   PubMed Web of Science ®Google Scholar
• Funk S, Miller MM, Mishell DR, et al Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319–26.
   PubMed Web of Science ®Google Scholar